Innovating Works

eTheRNA

Desconocido
TIGER: Proof of Principle of the best in class therapeutic mRNA cancer vaccine ETHERNA IMMUNOTHERAPIES tramitó un H2020: H2020-SC1-BHC-2018-2020 TIGER delivers proof of principle (PoP) in humans for a novel best-in-class therapeutic mRNA cancer vaccine platform optimized for intraveno...
2021-02-15 - 2025-07-31 | Financiado
EXPERT: EXpanding Platforms for Efficacious mRNA Therapeutics ETHERNA IMMUNOTHERAPIES participó en un H2020: H2020-SC1-BHC-2018-2020 The overall objective of EXPERT is to create an off-the-shelf mRNA-delivering nanomedicine platform that is manufactured via a quality-by-de...
2019-07-03 - 2025-02-28 | Financiado
HIVACAR: Evaluating a Combination of Immune based Therapies to Achieve a Functional Cure of HIV Infection ETHERNA IMMUNOTHERAPIES participó en un H2020: H2020-SC1-2016-2017 The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control o...
2016-12-12 - 2022-06-30 | Financiado
IHIVARNA: Therapeutic TriMix mRNA based Vaccine in Chronic HIV 1 Infected Patients Receiving Antiretroviral... ETHERNA IMMUNOTHERAPIES participó en un FP7: To find a therapy alternative to cART for life is one of the hot topics of investigation in HIV field. Therapeutic vaccination seems to be t...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.